Myriad Genetics (MYGN) reported Q4 adjusted earnings late Monday of $0.03 per diluted share, down from $0.04 a year earlier.
Analysts polled by FactSet expected $0.03.
Revenue for the quarter that ended Dec. 31 was $210.6 million, up from $196.6 million a year earlier.
Analysts surveyed by FactSet expected $211.6 million.
The company expects a Q1 adjusted loss per share of $0.04 to $0.08 and 2025 adjusted EPS of $0.07 to $0.11, which it said is in line with its prior outlook. Analysts surveyed by FactSet expect a loss of $0.03 and earnings of $0.04, respectively.
The company expects Q1 revenue between $196 million and $204 million and continues to expect full-year revenue of $840 million to $860 million. Analysts polled by FactSet expect $206.6 million and $860.8 million, respectively.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。